



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0315

Inventors: Salceda et al.

Serial No.: 10/076,747

Filing Date: February 13, 2002

Examiner: Cynthia B. Wilder

Group Art Unit: 1637

Title: Compositions and Methods Relating to
Ovarian Specific Genes and Proteins

"Express Mail" Label No. EV540196777US
Date of Deposit July 30, 2004

I hereby certify that this paper is being deposited with the
United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Commissioner for Patents
Post Office Box 1450, Box RCE, Alexandria, VA 22313-1450

By Kathleen A. Tyrell
Typed Name: Kathleen A. Tyrell, Reg. No. 38,350

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,




Kathleen A. Tyrrell
Registration No. 38,350

Date: July 30, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

Form PTO-1449 Modified		Docket No. DEX-0315	Serial No. 10/076,747
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Salceda et al.	
		Filing Date February 13, 2002	Group 1637
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	NCBI Genbank Accession No: NM_152855 [gi:23110979] 18 September 2002 with Revision History	
	AB	NCBI Genbank Accession No: NM_020070 [gi:13399297] 21 March 2001 with Revision History - The Revision History of 23110977 which replaces 13399297 is provided	
	AC	Hollis et al., "Immunoglobulin λ light-chain-related genes 14.1 and 16.1 are expressed in pre-B cells and may encode the human immunoglobulin ω light-chain protein" Proc. Natl. Acad. Sci. USA 1989 86:5552-5556	
EXAMINER		DATE CONSIDERED	